The Critical Role of 2-Bromo-8-fluoro-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one in Pharmaceutical Synthesis
In the complex landscape of modern pharmaceutical development, specific chemical intermediates play a pivotal role in enabling the synthesis of life-saving drugs. One such compound that has garnered significant attention is 2-Bromo-8-fluoro-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one, identified by its CAS number 283173-80-8. This fluorinated heterocyclic compound is indispensable for the production of Rucaparib, a potent PARP inhibitor used in cancer therapy. As a leading manufacturer and supplier, NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to providing high-quality 2-Bromo-8-fluoro-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one to researchers and pharmaceutical companies worldwide.
The synthesis of complex pharmaceutical molecules often relies on the availability of precisely engineered building blocks. 2-Bromo-8-fluoro-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one, with its distinct chemical structure featuring both bromine and fluorine atoms, offers unique reactivity that is crucial for multistep organic synthesis pathways. The presence of the indole and azepine ring systems, fused together, provides a rigid scaffold that can be further functionalized to achieve specific pharmacological properties. Understanding the demand for high purity pharmaceutical intermediate, our production processes are optimized to yield this compound with a purity of 98.0% or higher, ensuring the integrity and efficacy of the final drug product.
The importance of this chemical intermediate extends beyond its role in Rucaparib synthesis. As a versatile heterocyclic chemical intermediate, it is a valuable asset for researchers exploring new therapeutic targets and developing novel drug candidates. The strategic introduction of fluorine atoms, as seen in this molecule, can significantly influence a drug's metabolic stability, lipophilicity, and binding affinity to its target protein, thereby enhancing its pharmacokinetic profile. NINGBO INNO PHARMCHEM CO.,LTD. recognizes the critical need for reliable suppliers in this field, and we are committed to meeting the evolving needs of the pharmaceutical R&D sector. We strive to be a go-to source for fluorinated organic building blocks, facilitating breakthroughs in medicinal chemistry.
For companies looking to procure this essential compound, exploring options for its buy/purchase is a critical step. NINGBO INNO PHARMCHEM CO.,LTD. offers competitive price points for its 2-Bromo-8-fluoro-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one, ensuring that cost-effectiveness does not compromise quality. Our efficient manufacturing capabilities and robust supply chain management allow us to consistently deliver this chemical intermediate, supporting the continuous production pipelines of our clients. We pride ourselves on being a dependable manufacturer in China, capable of fulfilling both small-scale research requirements and larger production volumes.
In conclusion, 2-Bromo-8-fluoro-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one (CAS: 283173-80-8) stands as a testament to the intricate chemistry that underpins modern medicine. NINGBO INNO PHARMCHEM CO.,LTD. is proud to be a key contributor in this domain, providing the essential building blocks that drive pharmaceutical innovation. We invite researchers and developers to connect with us for their supply of this critical intermediate and to explore how our commitment to quality and service can benefit their projects.
Perspectives & Insights
Future Origin 2025
“One such compound that has garnered significant attention is 2-Bromo-8-fluoro-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one, identified by its CAS number 283173-80-8.”
Core Analyst 01
“This fluorinated heterocyclic compound is indispensable for the production of Rucaparib, a potent PARP inhibitor used in cancer therapy.”
Silicon Seeker One
“is dedicated to providing high-quality 2-Bromo-8-fluoro-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one to researchers and pharmaceutical companies worldwide.”